Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2017, Article ID 2683478, 3 pages
https://doi.org/10.1155/2017/2683478
Case Report

Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism

1Lille II University Medical School, Lille, France
2CHU Lille, Service de Toxicologie et Génopathies, Lille, France
3Medical Oncology Department, Oscar Lambret Cancer Centre, Lille, France
4Medical Oncology Department, Amiens University Hospital, Amiens, France

Correspondence should be addressed to Nicolas Penel; rf.terbmal-o@lenep-n

Received 8 June 2017; Accepted 17 August 2017; Published 26 September 2017

Academic Editor: Jose I. Mayordomo

Copyright © 2017 Arnaud Jannin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Ruiz-Mesa, J. M. Goldberg, A. J. Coronado Munoz, S. N. Dumont, and J. C. Trent, “Rhabdomyosarcoma in Adults: New Perspectives on Therapy,” Current Treatment Options in Oncology, vol. 16, no. 6, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. O. Oberlin, A. Rey, J. Sanchez De Toledo et al., “Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study,” Journal of Clinical Oncology, vol. 30, no. 20, pp. 2457–2465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Bagatell, R. Norris, A. M. Ingle et al., “Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a children's oncology group study,” Pediatric Blood and Cancer, vol. 61, no. 5, pp. 833–839, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Beutler, T. Gelbart, and A. Demina, “Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 14, pp. 8170–8174, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Matsui, Y. Maruo, H. Sato, and Y. Takeuchi, “Combined effect of regulatory polymorphisms on transcription of UGT1A1 as a cause of Gilbert syndrome,” BMC Gastroenterology, vol. 10, article no. 57, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Iyer, C. D. King, P. F. Whitington et al., “Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes,” The Journal of Clinical Investigation, vol. 101, no. 4, pp. 847–854, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Kadakol, S. S. Ghosh, B. S. Sappal, G. Sharma, J. R. Chowdhury, and N. R. Chowdhury, “Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: Correlation of genotype to phenotype,” Human Mutation, vol. 16, no. 4, pp. 297–306, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Innocenti, D. L. Kroetz, E. Schuetz et al., “Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics,” Journal of Clinical Oncology, vol. 27, no. 16, pp. 2604–2614, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Del Re, C. Cremolini, and F. Loupakis, “DPYD c.1905 + 1G > A and c.2846A > T and UGT1A1 *28 allelic variants as predictors of toxicity: pharmacogenetic translational analysis from the Phase III TRIBE study in metastatic colorectal cancer,” Journal of Clinical Oncology, pp. 33–3532, 2015. View at Google Scholar
  10. E. Marcuello, D. Páez, L. Paré et al., “A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer,” British Journal of Cancer, vol. 105, no. 1, pp. 53–57, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. E. V. Cutsem, A. Cervantes, R. Adam et al., “ESMO consensus guidelines for the management of patients with metastatic colorectal cancer,” Annals of Oncology, vol. 27, pp. 1386–1422, 2016. View at Google Scholar
  12. NCCN Guidelines–Colon Cancer, 2017, http://www.jnccn.org/content/15/3/370.full.pdf+html.
  13. Camptosar [prescribing information], 2017, http://labeling.pfizer.com/ShowLabeling.aspx?id=533.
  14. S. Quaranta and F. Thomas, “Pharmacogenetics of anti-cancer drugs: state of the art and implementation—recommendations of the French National Network of Pharmacogenetics,” Therapie, vol. 72, no. 2, pp. 205–215, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Roncato, E. Cecchin, M. Montico et al., “Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype,” Clinical Pharmacology and Therapeutics, 2017. View at Publisher · View at Google Scholar · View at Scopus